This report on the breast cancer therapeutics market studies the current as well as future prospects of the market globally. The stakeholders of this report include pharmaceutical companies and intermediaries engaged in the new drug discovery, pipeline development of various breast cancer therapeutics as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global breast cancer therapeutics market with respect to the leading market segments in terms of geography.
The global breast cancer therapeutics market has been studied based on major drug class segments, and their regional as well as national markets. Based on drug class, the global market has been categorized into five major segments: HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptors. The market for these segments and sub-segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn and compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all segments, considering 2014 as the base year.
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the breast cancer therapeutics market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is illustrated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market.
Geographically, the breast cancer therapeutics market has been segmented into five regions: North America (the U.S. and Canada), Europe (the U.K., Germany, and Rest of Europe), Asia Pacific (Japan, South Korea, and Rest of APAC), Latin America (Brazil and Rest of Latin America), and Middle East & Africa (MEA). Market revenue in terms of US$ Mn and CAGR % from 2015 to 2023 are provided for all the regions and countries, considering 2014 as the base year.
The recommendations section included in the report would assist existing market players in expanding their market shares and new pharmaceutical companies in establishing their presence in the global breast cancer market. The report also profiles leading and emerging new players in the breast cancer therapeutics market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.
The global breast cancer therapeutics market has been segmented as follows:
Global Breast Cancer Therapeutics Market, by Drug Class
- Global HER2 Inhibitors Market Revenue, 2015–2023 (US$ Mn)
- Herceptin (Trastuzumab)
- Tykerb (Lapatinib)
- Perjeta (Pertuzumab)
- Kadcyla (Ado-trastuzumab emtansine)
- Global Mitotic Inhibitors Market Revenue, 2015–2023 (US$ Mn)
- Halaven (Eribulin)
- Taxotere (Docetaxel)
- Ixempra (Ixabepilone)
- Global Anti-metabolites Market Revenue, 2015–2023 (US$ Mn)
- Gemzar (Gemcitabine)
- Global Aromatase Inhibitors Market Revenue, 2015–2023 (US$ Mn)
- Femara (Leterozole)
- Aromasin (Exemestane)
- Arimidex (Anastrozole)
- Ibrance (Palbociclib)
- Afinitor (Everolimus)
- Global Hormone Receptor Market Revenue, 2015–2023 (US$ Mn)
Global Breast Cancer Therapeutics Market, by Geography
- North America
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa (MEA)
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
2 Executive Summary
2.1 Global Breast Cancer Therapeutics: Market Snapshot
2.2 Global Breast Cancer Therapeutics Market Share, by Geography, 2014 & 2023(Value %)
2.3 Global Breast Cancer Therapeutics Market, by Drug Class, 2014 & 2023 (Value %)
3 Global Breast Cancer Therapeutics Market - Market Overview
3.1 Market Definition and Overview
3.2 Epidemiology & High Risk Groups
3.3 Diagnosis and Types of Breast Cancer
3.4 Other Breast Cancer Therapies
3.5 Market Dynamics
22.214.171.124 Higher Incidence Rate
126.96.36.199 Demographic Transition
188.8.131.52 Rising Prevalence Of Obesity
184.108.40.206 Diagnostic Screening Programs
220.127.116.11 Increase in Private Health Insurance Plans:
18.104.22.168 Generic Drugs: Substitute Branded Drugs
22.214.171.124 Intense Competition: Fall in Prices
126.96.36.199 Access barriers due to high drug costs
188.8.131.52 Absence of Social Health Insurance
184.108.40.206 Serious Side Effects of Breast Cancer Therapeutics
220.127.116.11 Countries Lacking Women Empowerment
18.104.22.168 Newer medication options
22.214.171.124 Potential Growth of Domestic Pharmaceutical Companies
126.96.36.199 Combination Drug Therapy
188.8.131.52 Technological Advancements and Robust Trends of Drug Approval
184.108.40.206 New Companion Diagnostics Models
220.127.116.11 Drug Therapy for Triple Negative (TNBC)
18.104.22.168 Approval for Multiple Indications (positive & negative types) HER2 breast cancer
3.7 Market Attractiveness Analysis– Breast Cancer Therapeutics Market, by Geography (2014) (%)
3.8 Competitive Landscape – Breast Cancer Therapeutics Market, by Key Players, 2014 (%)
4 Market Segmentation – By Drug Class
4.2 Global HER2 Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.2.1 Herceptin (Trastuzumab)
4.2.2 Tykerb (Lapatinib)
4.2.3 Perjeta (Pertuzumab)
4.2.4 Kadcyla (Ado-trastuzumab emtansine)
4.3 Global Mitotic Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.3.1 Halaven (Eribulin)
4.3.2 Taxotere (Docetaxel)
4.3.3 Ixempra (Ixabepilone)
4.4 Global Anti-metabolites Market Revenue, 2015–2023 (US$ Mn)
4.4.1 Gemzar (Gemcitabine)
4.5 Global Aromatase Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.5.1 Femara (Leterozole)
4.5.2 Aromasin (Exemestane)
4.5.3 Arimidex (Anastrozole)
4.5.4 Ibrance (Palbociclib)
4.5.5 Afinitor (Everolimus)
4.6 Global Hormone Receptor Market Revenue, 2015–2023 (US$ Mn)
5 Market Segmentation – By Geography
5.2 Global Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.3 North America Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.4 Europe Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.4.4 Rest of Europe
5.5 Asia Pacific Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.5.2 South Korea
5.5.3 Rest of Asia Pacific
5.6 Rest of the World
5.6.1 Latin America
22.214.171.124 Rest of Latin America
5.6.2 Middle East and Africa
7 Company Profiles
7.1 AstraZeneca plc
7.2 Eisai Co., Ltd.
7.3 Eli Lilly and Company
7.4 F. Hoffmann-La Roche Ltd.
7.5 GlaxoSmithKline plc
7.6 Novartis International AG
7.7 Pfizer, Inc.
7.8 Puma Biotechnology, Inc.
7.9 Sanofi S.A.
7.10 Teva Pharmaceutical Industries Ltd.
Breast cancer is the second-largest cause of cancer deaths globally. Breast cancer treatment is seen as a major focus area for governments in several developed and developing countries due to growing awareness about the disease. Drugs used in the treatment of breast cancer range from regular regimens to biologicals. The market is witnessing strong growth driven by increasing awareness among the population and premium priced therapies being introduced by pharmaceutical manufacturers. Moreover, drugs for breast cancer have seen accelerated approvals, thereby providing impetus for breast cancer research and shifting the equilibrium toward research of new effective pathways for intervention of breast cancer.
The major classes of drugs for breast cancer are HER2 inhibitors, anti-metabolites, aromatase inhibitors, mitotic inhibitors, and hormone receptors antagonists. The HER2 inhibitors segment dominated the market in 2014. High cost and accurate diagnosis are attributed to the dominance of the segment of the breast cancer therapeutics market. On the other hand, recently launched molecule, Ibrance, is projected to be the fastest growing drug in the breast cancer therapeutics market.
Geographically, North America dominated the global breast cancer therapeutics market in 2014 due to favorable insurance system that entitles high price of products. Moreover, entry of major pharmaceutical companies in the U.S. and high prevalence of breast cancer are the other factors that drive the market in North America. The market in Asia Pacific is anticipated to witness the fastest growth due to rising incidence, growing awareness about breast cancer, and standpoint taken by major governments of APAC countries to alleviate breast cancer as national health program.
The breast cancer therapeutics market exhibits strong demand for combination therapies to increase the overall efficiency of the treatment. Major players operating in the breast cancer therapeutic market are Genentech, Inc. (a Roche company), Eisai Co. Ltd., Eli Lilly and Company, Pfizer, Inc., Novartis AG, AstraZeneca plc, and Sanofi S.A.